Sponsor Oversight Under ICH E6(R3)
The regulatory bar has moved: oversight must be risk-based and technology-enabled. One agent layer gives sponsors a live, auditable view of the whole trial.
The FDA found it. Why didn't we?
The trial lifecycle was built as a sequence of handoffs, not a system, and intelligence is lost at every one. The regulatory bar has moved: oversight must be risk-based and technology-enabled.
Risk-based, quality-by-design oversight
The first GCP overhaul in three decades — explicitly embracing modern technology, data governance, and risk-based monitoring across the trial.
AI must be credible & risk-assessed
The FDA’s first framework for AI in drug development sets a risk-based bar for the credibility of any model that informs a regulatory decision.
Innovo Copilot
One Record For Sponsor And CRO
An orchestration layer across every process, source and system
One live site-risk score across EDC / CTMS / eTMF
Role-based dashboards grounded in the plan
Breach → CAPA → verified closure, automatically
Data lineage and audit trails for every AI-generated insight
The Outcomes Clinical Teams Care About
-
24/7
Audit readiness: continuous data lineage tracking
-
~80%
Faster breach-to-CAPA
-
Real-Time
Closed loop risk-based monitoring
Frequently Asked Questions
Plain answers on sponsor oversight and ich e6(r3).
-
ICH E6(R3), adopted by the FDA in September 2025, is the first GCP overhaul in three decades. It explicitly embraces modern technology, data governance, and risk-based monitoring across the trial. In practice, oversight has to be risk-based and technology-enabled, including for work a sponsor outsources.
-
By working on the same live record as the CRO. Innovo Copilot gives both sides one live site-risk score across EDC, CTMS and eTMF, role-based dashboards grounded in the plan, and an audit trail from each breach to its verified closure.
-
A single layer of AI agents reasoning across every process, every source, and every system, so intelligence never gets lost in the handoff. It works across the systems a trial already runs on, such as EDC, CTMS and eTMF.
-
A system of insight shows a risk. A system of action attaches the right action to it and follows it to closure. Innovo Copilot surfaces risk as it emerges, tied to its timeline impact, with the right action attached: breach → CAPA → verified closure.
Part Of Innovo Copilot
Oversight is built on the same closed loop: Plan → Author → Monitor. Every phase feeds the next. More solutions: Protocol Authoring · Amendments & Deviations · Risk-Based Monitoring & CAPA · Study Startup.
Ready To Accelerate Clinical Trial Execution?
Connect with our team today to see how the Innovo platform can transform your operational efficiency.